Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to invite shareholders, investors and interested parties to an online update on the recent announcement regarding the application for PromarkerD s listing on the Australian Medicare Benefits Schedule hosted by MD, Dr Richard Lipscombe.
New study finds 1-in-5 patients at high risk of cardiovascular disease decline statin therapy with women being 20 percent more likely to refuse it when first suggested and 50 percent more likely than men to never accept the recommendation.
Proteomics International Laboratories Ltd (ASX:PIQ) advises that it is in the closing stages of finalising the detailed terms of its Exclusive Licence Agreement with Sonic Healthcare USA for use of the Company s PromarkerD predictive test for diabetic kidney disease in the United States.
/PRNewswire/ The "Renal Biomarkers: Technologies and Global Markets" report has been added to ResearchAndMarkets.com s offering. This report incorporates an.